"TAP não sobrevive se se mantiver pública", garante Pinto Luz

[Marck]

[Evv]

o reverse split estava marcado para dia 1, tendo no entanto sido adiado. até subiu alguma coisa à conta de especulações sobre esse adiamento.

se olharmos para um grafico deverá ter algum suporte por volta dos .006 . Já tenho o meu baú delas se descer daquele valor começo a pensar em ir reforçando.


abçs e bn

[pisão]

Vai subir nos próximos dias. eheheheheheheh

Reverse split 1:50:
(...)

Isto é que vai ser ganhar dinheiro, aumentar 50 vezes não é para qualquer uma

bem, um fico de muito longe a observar...

Não é aumentar, é diminuir.
Quem tem 50 irá receber apenas uma.
Estou de fora, mas acho que poderá cair ainda mais

[cannot]

Vai subir nos próximos dias. eheheheheheheh

Reverse split 1:50:
(...)

Isto é que vai ser ganhar dinheiro, aumentar 50 vezes não é para qualquer uma

bem, um fico de muito longe a observar...

[englishman]

Vai subir nos próximos dias. eheheheheheheh

Reverse split 1:50:

Board of Directors of Genta Incorporated Announce Reverse Split of Company’s Common Stock

Proposal Authorized by Stockholders to be Implemented at Ratio of 1:50

BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Genta Incorporated (OTCBB: GNTA.OB) announced today that its Board of Directors has approved a one-for-fifty reverse stock split of Genta’s Common Stock, and that the split will be effective with the open of trading on July 1, 2009. At the Special Meeting of stockholders held on June 26, 2009, Genta’s stockholders approved a proposal authorizing the Board of Directors, in its discretion, to effect a reverse split of Genta’s outstanding common stock at a ratio within a specified range.

In the reverse split, each fifty (50) shares of Genta common stock issued and outstanding will be combined into one (1) share of common stock. Following the reverse split, the total number of shares outstanding will be reduced to approximately 100 million shares. Additionally, the reverse split will affect the conversion ratio for all instruments convertible into shares of Genta common stock including its convertible notes, outstanding warrants and outstanding stock options.

As a result of the reverse stock split, holders of certificates representing shares of “old” Genta Common Stock prior to the effective date have the right to receive, upon surrender of those certificates, “new” shares of Genta Common Stock at the ratio of one share of “new” Common Stock for every fifty shares of “old” Common Stock. No fractional shares will be issued in connection with the reverse stock split. Instead, holders of “old” shares who otherwise would have received fractional shares will receive an amount in cash equal to the value of such fractional shares based on the closing price of Genta’s Common Stock on June 30, 2009.

Existing stockholders holding Genta Common Stock certificates will receive a Letter of Transmittal from the Company’s transfer agent, BNY Mellon Shareowner Services, with specific instructions regarding the exchange of shares. Questions regarding this exchange process can be addressed by contacting BNY Mellon Shareowner Services at 1-800-777-3674 (or 1-201-680-6654 from outside the U.S.).

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company’s research platform: DNA/RNA-based Medicines and Small Molecules. Genasense® (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. The leading drug in Genta’s Small Molecule program is Ganite® (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, that has recently entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drugs as paclitaxel and docetaxel. Ganite and Genasense are available on a “named-patient” basis in countries outside the United States. For more information about Genta, please visit our website at: www.genta.com.

Safe Harbor

This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Such forward-looking statements include those that express plan, anticipation, intent, contingency, goals, targets, or future developments and/or otherwise are not statements of historical fact. The words “potentially”, “anticipate”, “could”, “calls for”, and similar expressions also identify forward-looking statements. The Company does not undertake to update any forward-looking statements. Factors that could affect actual results include, without limitation, risks associated with:

* the Company’s ability to obtain necessary regulatory approval for Genasense® from the U.S. Food and Drug Administration (“FDA”);
* the safety and efficacy of the Company’s products or product candidates;
* the Company’s assessment of its clinical trials;
* the commencement and completion of clinical trials;
* the Company’s ability to develop, manufacture, license and sell its products or product candidates;
* the Company’s ability to enter into and successfully execute license and collaborative agreements, if any;
* the adequacy of the Company’s capital resources and cash flow projections, the Company’s ability to obtain sufficient financing to maintain the Company’s planned operations, or the Company’s risk of bankruptcy;
* the adequacy of the Company’s patents and proprietary rights;
* the impact of litigation that has been brought against the Company; and
* the other risks described under Certain Risks and Uncertainties Related to the Company’s Business, as contained in the Company’s Annual Report on Form 10-K and Quarterly Report on Form 10-Q.

There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report on Form 10-K for 2008 and its most recent quarterly report on Form 10-Q.

[Veggix]

Esta acção não está cotada em OTC?

[MERCW125]

Esta é daquelas em podemos acordar ricos no dia seguintes.
Ricos talvez não mas quem tiver algumas poderá ficar remediado com mais valias de 1500% num dia tal como foi o caso da TTNP, que cotava a 0.04 e quando aprovaram um medicamento abriu a 1,65USD.
Este tipo de acçoes e para ir comprando devagarinho e esquecer.
Penso que terá futuro.

[Evv]

maus resulyados, out of funding, reverse split para proximo. tem no entanto 3 medicamentos em phase 3

abçs e bn

[Marck]

Alguem sabe o porquê da queda deste papel nos ultmos anos?????????



Bons Negocios